The Effectiveness of Paroxetine on Cognitive and Emotional Symptoms of Social Anxiety Disorder

Document Type : Research Paper

Authors

1 Ph.D. in psychology, Department of psychology, Khorasan e Razavi Science and Research Branch,Islamic Azad University, Neyshabur, Iran

2 Ph.D in psychology, Department of psychology, Khorasan e Razavi Science and Research Branch,Islamic Azad University, Neyshabur, Iran

3 Ph.D. in clinical psychology, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Abstract
Introduction: This study is a clinical trial with trial ID 4N20171228038109, which aimed to evaluate the effectiveness of paroxetine on social anxiety disorder.
Materials and Methods: The statistical population of this study included all those referring to psychiatric services and private psychiatric offices diagnosed with social anxiety disorder in Mashhad city during the years 1396-96 in Specialized Psychological Center. In the current study, 24 of these patients were selected by purposive sampling and were randomly assigned to the groups. Research variables were measured by Spin Social Anxiety Inventory (2000), Beck Depression Inventory, World Health Organization Short Form Quality of Life Scale (1989), and Wilson & Rappi (2005) Social Negative Events Consequences. And evaluated 3 months after drug treatment with paroxetine.
Results: Statistical analysis of current research data using repeated measures ANOVA showed that in general, paroxetine was significantly (p <0.05) effective on the dependent variables.
Conclusion: Paroxetine was significantly effective in the post-test phase on most of the components of the dependent variables and was not statistically significant in the follow-up phase. The control group also showed no significant difference in the three stages of the test.

Keywords

References

1-      Tiwari N, Baldwin. DS. Yogic breathing techniques in the management of anxiety and depression: systematic review of evidence of efficacy and presumed mechanism of action. Anxiety 2018; 3:220-8.
2-      Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch General Psychiatry 2005; 62:617-27.
3-      Gottlieb SS, Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J 2007; 153:868-73.  
4-      Hoff LA, Morgan BD. Psychiatric and mental health essentials in primary care. Abingdon: Routledge; 2010.
5-      Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21:718-79.
6-      Martinez‐Martin P, Rojo‐Abuin JM, Dujardin K, Pontone GM, Weintraub D, Forjaz MJ, et al. Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. Eur J Neurol 2013; 20:1198-203.
7-      Allen F, Fisher M, Phipps N. The correlation between depression and diabetes. US Pharma 2014; 39:12-5.
8-      Stefanova E, Ziropadja L, Petrović M, Stojković T, Kostić V. Screening for anxiety symptoms in Parkinson disease: a cross-sectional study. J Geriatric Psychiatry Neurol 2013; 26:34-40.
9-      Dozeman E, van Schaik DJ, van Marwijk HW, Stek ML, Beekman AT, van der Horst HE. Feasibility and effectiveness of activity-scheduling as a guided self-help intervention for the prevention of depression and anxiety in residents in homes for the elderly: a pragmatic randomized controlled trial. Int Psychogeriatr 2011; 23:969-78.
10-  Spence SH, Rapee RM. The etiology of social anxiety disorder: an evidence-based model. Behav Res Ther 2016; 86:50-67.
11-  Kishi T, Matsuda Y, Matsunaga S, Moriwaki M, Otake Y, Akamatsu K, et al. Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial. Neuropsychiatr Dis Treat 2017; 13:117.
12-  Otsubo T, Watanabe Y, Hongo S, Inoue M, Akimoto K, Murakami K, et al. Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study. Neuropsychiatr Dis Treat 2018; 14:955.
13-  Kubzansky LD, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease? J Psychosomatic Res 2000; 48:323-37.
14-  Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PloS One 2014; 9:e106337.
15-  Harmer D, Phil CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 2009; 166:1178-84.
16-  Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160:749-56.
17-  Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch General Psychiatry 2004; 61:1153-62.
18-  Olfson M, Kroenke K, Wang S, Blanco C. Trends in office-based mental health care provided by psychiatrists and primary care physicians. J Clin Psychiatry 2014; 75:247-53.
medical journal of mashhad university of medical sciences
Volume 62, Issue 4
November and December 2019
Pages 1587-1593

Files

Share

How to cite

Statistics